- Disease profiling
- Drug target discovery / validation
- Drug discovery
- ADMET
- Preclinical development
- Pharmacokinetics
- Drug metabolism
- Toxicology
- Clinical research
- Screening
- Functional genomics
Conference programme
8:30 Registration & Coffee9:00 Chairman's Opening RemarksRami Hannoush, Scientist, Genentech 9:10 KEYNOTE PRESENTATION: AN OVERVIEWKhalid Khabar, Director, Biomolecular Program, Faisal Specialist Hospital & Research Centre Key elements of cell-based assaysOverview of technologies used and applicationsExpanding possibilities and market trendsExamples from real laboratory life9:40 THE CELL-BASED ASSAYS MARKETLaleh Safinia, Research Analyst, Frost & Sullivan Identification of challenges and drivers facing the European cell-based assays marketForecasts for the European cell-based assays marketTechnology and end-user trends for the European cell-based assays marketStrategic recommendations for the European cell-based assays market10:10 Morning Coffee10:40 ANTIBODY ASSAYSYoram Reiter, Head, Laboratory of Molecular Immunology, Technion - Israel Institute Of Technology 11:10 HIGH CONTENT SCREENING THROUGH FLOW CYTOMETRYAbder Mahfoudi, Head of Business Development, Fluofarma Fully Automated flow cytometry platform for High Content Screening Cell-based assays and multiplexed functional readouts in single cells Biosensors for the quantitative analysis of target protein localization and activity, using flow cytometry Improving the throughput and screening content for in vitro target validation Multiparametric profiling of anti-cancer drugs11:50 HIGH-CONTENT ASSAYS: MULTIPARAMETER IMAGING ASSAYS FOR CNS RESEARCHAndreas Scheel, Head, Cellular Assays, Evotec Pathway and phenotypic read-outs for compound screeningUse of cell lines and primary neuronsMultiparameter read-outsComputational tools for data analysis12:20 Networking Lunch13:20 ION CHANNELS ASSAYSRochdi Bouhelal, Research Investigator, Novartis Pharma 13:50 PROFILING P53 NETWORKS BY CELL-BASED MULTIPLEX IMAGINGRami Hannoush, Scientist, Genentech A multiplex cell-based imaging assay was developed to detect cellular activation of p53Using the above assay, RNA interference and small molecule screens were conducted in parallel to identify regulators of the p53 pathwayThese results lead to a systems understanding of the p53 interaction network and to identifying novel therapeutic targets 14:20 APPLICATION OF FROZEN CELLSAlison Griffen, Associate Team Leader, Astrazeneca Benefits and limitationsImpact on time, resources and data accuracyBatch to catch consistencyCryopreservation of transiently transfected cells15:00 Afternoon Tea15:30 INNOVATIVE TISSUE CULTURE MODELS TO PREDICT DRUG EFFICACYCatherine Booth, Founder and MD Contract Research Services, Epistem Cancer stem cell and angiogenesis models Skin and intestinal models Improved candidate selection, earlier identification of adverse effects Proof of concept / mechanism of action16:00 ADAPTING COMPLEX HIGH CONTENT IMAGING ASSAYS TO HIGH DENSITY FORMATSVincent Unterreiner, Scientist, Center for Proteomic Chemistry, Novartis Pharma - High content screening in 1536 well plate format
- Infrastructure needed to perform non homogenous imaging assays (devices and automated platforms)
- Cell migration assay implementation into screening format
16:30 ONCOLOGY ASSAYSRob Howes, Research Director, Horizon Discovery Key issues to considerRecent developments in the field Analysing novel methodologiesAdvantages of automationIntegration of cell based assays with in vivo models of cancer 17:00 Chairman’s Closing Remarks and Close of Day One8:30 Registration & Coffee9:00 Chairman's Opening RemarksKhalid Khabar, Director, Biomolecular Program, Faisal Specialist Hospital & Research Centre 9:10 CONSIDERING HIGH-CONTENT SCREENING AND LABEL-FREE SCREENING TO MAKE THE BEST SCREENING CHOICESDominique Perrin, Group Leader, Molecular and Cellular Lead Discovery, Merck Serono Screening strategiesProfiling experiments and the application of the acquired data Analysing the specificity of antibodies against other receptorsEvaluating detection technology9:40 APPLICATIONS AND STRATEGIES FOR GPCR IMPEDANCE ASSAY TECHNOLOGIES USING PRIMARY CELLSOliver Nayler, Director, Head of Molecular Biology, Actelion Primary versus recombinant cellsLabel-free assaysAre pathway predictions possible 10:10 PRINCIPLES AND APPLICATIONS OF LABEL-FREE CELL BASED ASSAYS USING THE CORNING® EPIC® SYSTEMMaria Torvinen, Field Application Scientist, Corning Benefits of Label-Free DetectionDynamic Mass Redistribution - What do we measure?Detection of integrated cellular pathways in one shot - what are you missing with more conventional detection methods? Examples of Epic® cell based assays10:50 Morning Coffee11:20 HIGH THROUGHPUT SCREENING ANALYSIS FOR GENOTOXICITY AND CLASTOGENICITY Willem Schoonen, Group Leader, Schering-Plough Research Institute Genotoxicity screening with Salmonella: comparison of the VitotoxTM test with literature data for the full Ames test Clastogenicity screening with yeast: comparison of the GreenScreen GC and RadarScreen tests with literature data from in vitro micronuclei and chromosomal aberration testsClastogenicity screening with human liver HepG2 cells: comparison of three different promoter settings involved in chromosomal repair11:50 HIGH THROUGHPUT SCREENING OF BIOLOGICSPaula Harrison, Head of High Throughput Screening, Medimmune Assays used to screen for functional antibodiesChallenges of screening un-purified biologics in cell-based assaysCharacterisation of purified biologicsImplementing cell-based assays in the future12:20 Networking Lunch13:20 CELL CULTURE SOLUTIONS FOR YOUR LABORATORYComplete detection systems for respiratory viruses, herpesviruses, enterovirusesELVIS® Flu cell system for influenza serum neutralisation assays and TCID50 determinationPrimary hepatocytes for in vitro toxicology applicationsOther continuous cell lines and MAb’s for your applicationsHeather Baird Tomlinson, Senior Manager, Diagnostic Hybrids Patricia Harris, Executive Director of Worldwide Sales, Diagnostic Hybrids 14:00 HIGH CONTENT SCREENINGPhilip Denner, Scientist, Screening High-Content Analysis, Bayer Schering Pharma The use of imaging based assays and assessing their suitabilityQuantifying different cellular responses and phenotypesAnalysis cell counting, translocation, angiogenesis and cell apoptosisAnalysis techniques, data management and dye choices14:30 CELLULAR BIOENERGETICS IN A MICROPLATE: A NEW WINDOW ON METABOLISMDavid Ferrick, Chief Scientific Officer, Biology and Applications, Seahorse Bioscience Real time measurements of aerobic metabolism and glycolytic fluxDesigning complex experiments using automated drug injection portsCells can be grown/differentiated and analysed in the same microplateUsing bioenergetics to measure growth, differentiation and cell death15:00 Afternoon Tea15:30 DRIVING DRUG DISCOVERY PROGRAMS WITH PRIMARY PHARMACOLOGY DATA FROM CELL-BASED ASSAYSSimon Eaglestone, Senior Principal Scientist, Pfizer Global R&D Incorporation of cell-based assays into in vitro screening strategies for drug discoveryComparison of alternate assay formats, challenges and caveatsOptimisation of efficiency and data qualityData analysis, integration and visualisation16:00 CELL-BASED BIOMARKERS: A FRESH APPROACHRosalyn Forsey, Biomarker Specialist, LCG Bioscience Flow cytometryMultiplex analysisCytokinesEx vivo stimulation 16:30 AN INTEGRATED APPROACH TO KINASE INHIBITORS PROFILING Daniel D’Orazio, Research Investigator, Centre for Proteomic Chemistry / Expertise Platform Kinases, Novartis Signalling pathway profiling using RGAsSignalling pathway analysis using phosphoproteomics technologiesBeta lactamase reporter gene assaysReverse Protein ArraysMultiplexing readoutsIllustrative examples17:00 Chairman’s Closing Remarks and Close of ConferenceKhalid Khabar, Director, Biomolecular Program, Faisal Specialist Hospital & Research Centre
Workshops
Workshop Crowne Plaza Hotel - St James 18th November 2008 London, United Kingdom
copyright ©
2022
SAE Media Group
|